submit to the journals

ASH Highlights

flipper_slider

Editor's Choice

Dr Jean-Jacques Kiladjian summarises the unmet needs in the current standard of care for polycythemia vera (PV) and discusses the use of ruxolitinib in PV. The filming of this video was supported by Novartis....

ASH Highlights Videos

Mohamad Mohty talks about the emergence of novel therapies and treatments strategies and the place of stem cell transplantation in multiple myeloma.
Rodrigo T Calado discusses the role of telomere shortening in bone marrow failure at ASH 2017.
Joseph M Connors discusses the rationale, design and results of the ECHELON-1 study of combined brentuximab vedotin and chemotherapy.
John D Grainger talks about his management approach to pediatric ITP and the goals of the UK paediatric ITP registry at ASH 2017.
Wojciech Jurczak discusses the two phase III trials of rituximab biosimilars published earlier this year and how the European approval of rituximab biosimilars has impacted on follicular lymphoma treatment.
Eliezer Rachmilewitz discusses the current status of gene therapy and editing for hemoglobinopathies.
James B Bussel talks about the unmet needs in the treatment of adult and pediatric ITP, and the recent finding of fostamatinib in adult persistent/chronic ITP.
Oncology & Hematology Review's Editor-in-Chief Shaji Kumar discusses his highlights from ASH 2017 and the most exciting developments in myeloma to look out for in 2018.
Matthew J Matasar discusses the challenges of treating patients with lymphoma and the role of antibody-drug conjugates in the treatment regimen.
Dr Jean-Jacques Kiladjian summarises the unmet needs in the current standard of care for polycythemia vera (PV) and discusses the use of ruxolitinib in PV. The filming of this video was supported by Novartis. Speaker Disclosures: Novartis: advisory boards, institutional research grant; AOP...
Dr Shaji Kumar reviews the rationale for targeting the BCL-2 protein in multiple myeloma (MM) and the results of the recent phase I study of venetoclax. He also discusses selinexor combination therapy and the role of minimal residual disease in assessing response to therapies. FILMED AT THE...
Dr Mohamad Mohty discusses consolidation and maintenance therapy in multiple myeloma and whether these therapies can replace autologous stem cell transplantation (ASCT). FILMED AT THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING 2016, SAN DIEGO, CALIFORNIA, US
Dr Mohamad Mohty gives his thoughts on innovative cellular therapy products and how they will enhance outcomes for haploidentical stem cell transplantation (haplo-SCT) patients. FILMED AT THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING 2016, SAN DIEGO, CALIFORNIA, US
Dr Will Donnellan reviews the challenges in chimeric antigen receptor (CAR) T-cell therapy for acute myeloid leukemia (AML). He also gives us his thoughts on the lack of randomized trials for patients with refractory AML and discusses emerging antibody-based therapies. FILMED AT THE AMERICAN...
Dr Bruce Cheson reviews the current treatment landscape for non-Hodgkin lymphoma and discusses the results of the phase III GADOLIN study, comparing obinutuzumab plus bendamustine with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma. FILMED AT THE AMERICAN...